What are the properties of CBDA in supplements?

CBDA - References & External links

CBDA (Cannabidiolic Acid)

TBS Ingredient ID (TBSI ID):	ISEA11E0
Name
CBDA Synonyms:
Chemical Formula:
C22H30O4
Molecular Formula:
Classification Type	Identifier
PubChem CID: U.S. National Library of Medicine (PubChem)	160570
InChI Key: International Chemical Identifier hash (InChIKey) computed from chemical structure using the International Union of Pure and Applied Chemistry (IUPAC) standard	WVOLTBSCXRRQFR-DLBZAZTESA-N
CAS: A proprietary registry number assigned by the Chemical Abstracts Service (CAS) division of the American Chemical Society (ACS)	1244-58-2
NIST: The National Institute of Standards and Technology (NIST)	1244-58-2
ChemIDplus: United States National Library of Medicine - TOXNET (Toxicology Data Network).	1244-58-2
KEGG: Kyoto Encyclopedia of Genes and Genomes (KEGG)	C10784
EC Number: A seven-digit regulatory identifier currently assigned by the European Chemicals Agency (ECHA) known as a European Community (EC) number	423-050-9
ECHA: European Chemicals Agency.	100.102.162
ChEMBL: An open data resource of binding, functional and ADMET bioactivity data (ChEMBL)	CHEMBL498672
ChEBI: Chemical Entities of Biological Interest (ChEBI) - Dictionary of molecular entities focused on "small" chemical compounds. ChEBI is part of the EMBL-European Bioinformatics Institute.	3359 Show: Cannabidiolic Acid - description from ChEBI
MeSH® ID: Medical Subject Heading (MeSH)	C006884
DSSTox Substance ID: United States Environmental Protection Agency (EPA).	DTXSID80154318
LIPIDMAPS: LIPID MAPS Lipidomics Gateway	LMPK13120003
KNApSAcK: A Comprehensive Species-Metabolite Relationship Database	C00002642
UNII: FDA Substance Registration System - Unique Ingredient Identifier	FJX8O3OJCD

The references to scientific articles about CBDA are not meant to imply that any products treat, cure, or diagnose any disease or human condition. We encourage our audience to do their own research beyond the resources we have provided so your decision is as educated as possible.

• The general properties of CBDA:
  • RUSSO, Ethan B. Cannabis Therapeutics and the Future of Neurology. Frontiers in integrative neuroscience, 2018, 12: 51. PMID:30405366
  • NAVARRO, Gemma; et al. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB 1, CB 2 and CB 1/CB 2 heteromer receptors. Pharmacological Research, 2020, 159: 104940. PMID:32470563
    Conclusion: Results here reported and the recent elucidation of the three-dimensional structure of CB1 and CB2 receptors help understanding the mechanism of action that might be protective and the molecular drug-receptor interactions underlying biased signaling.
  • CITTI, Cinzia; et al. Analysis of cannabinoids in commercial hemp seed oil and decarboxylation kinetics studies of cannabidiolic acid (CBDA). Journal of Pharmaceutical and Biomedical Analysis, 2018, 149: 532-540. PMID:29182999
  • STONE, Nicole L.; et al. A systematic review of minor phytocannabinoids with promising neuroprotective potential. British Journal of Pharmacology, 2020, 177.19: 4330-4352. PMID:32608035
• The properties of CBDA boosting Brain / Mental Clarity:
  • HEN-SHOVAL, D.; et al. Acute oral cannabidiolic acid methyl ester reduces depression-like behavior in two genetic animal models of depression. Behavioural brain research, 2018, 351: 1-3. PMID:29860002
  • ESPEJO-PORRAS, Francisco; et al. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology, 2013, 75: 155-163. PMID:23924692
    Conclusion: Collectively, these results suggest that CBD may influence motor activity, in particular vertical activity, and that this effect seems to be dependent on its ability to target the 5-HT1A receptor, a mechanism of action that has been proposed to account for its anti-emetic, anxiolytic and antidepressant effects.